Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)
Avatrombopag is the newest thrombopoietin receptor agonist (TPO-RA) approved to treat immune thrombocytopenia (ITP). Real-world evidence regarding effectiveness/safety is limited. The Spanish ITP Group (GEPTI) performed a retrospective study with patients starting avatrombopag for the first time. A...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Conselleria de Salut i Consum del Govern de les Illes Balears |
| Repositorio: | Docusalut |
| Idioma: | inglés |
| OAI Identifier: | oai:docusalut.com:20.500.13003/21308 |
| Acceso en línea: | https://hdl.handle.net/20.500.13003/21308 |
| Access Level: | acceso abierto |
| Palabra clave: | Receptors, Thrombopoietin Aged Spain Adult Humans Hydrazines Middle Aged Pyrazoles Thiazoles Male Thiophenes Platelet Count Female Treatment Outcome Purpura, Thrombocytopenic, Idiopathic Retrospective Studies Púrpura Trombocitopénica Idiopática Resultado del Tratamiento Tiofenos Receptores de Trombopoyetina Femenino Tiazoles Masculino Recuento de Plaquetas Humanos Persona de Mediana Edad Hidrazinas Pirazoles Anciano Estudios Retrospectivos Adulto España |
| id |
ES_d5ee4dd2f9cfdbdb974060d45ad1b771 |
|---|---|
| oai_identifier_str |
oai:docusalut.com:20.500.13003/21308 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)Pascual-Izquierdo, CristinaSánchez-González, BlancaCanaro Hirnyk, MarianaGarcía-Donas, GloriaMenor-Gómez, MaríaGil-Fernández, Juan-JoséMonsalvo-Saornil, Silviade-Laiglesia, AlmudenaÁlvarez-Román, María TeresaJarque-Ramos, IsidroLlácer, María-JoséPedrote-Amador, BegoñaZafra-Torres, DenisCaparrós-Miranda, Isabel SocorroOrtúzar-Pasalodos, ArianaRevilla-Calvo, NuriaBastida, José-MaríaChica-Gullón, EstherAlvarellos, MontserratJiménez-Bárcenas, ReyesBernat-Pablo, SilviaMartínez-Carballeira, DanielLakhwani, SunilLópez-Ansoar, ElsaMoreno-Beltrán, María-EsperanzaLorenzo-Vizcaya, ÁlvaroAguirre, María-AránzazuLasa-Eguialde, MaialenCanet, MartaGonzález-Gascón-Y-Marín, Isabel-TeresaCaballero-Navarro, GonzaloCuesta, AmaliaDíaz-López, MartaArquero, TeresaMoreno-Carbonell, MartaMingot-Castellano, María-EvaReceptors, ThrombopoietinAgedSpainAdultHumansHydrazinesMiddle AgedPyrazolesThiazolesMaleThiophenesPlatelet CountFemaleTreatment OutcomePurpura, Thrombocytopenic, IdiopathicRetrospective StudiesPúrpura Trombocitopénica IdiopáticaResultado del TratamientoTiofenosReceptores de TrombopoyetinaFemeninoTiazolesMasculinoRecuento de PlaquetasHumanosPersona de Mediana EdadHidrazinasPirazolesAncianoEstudios RetrospectivosAdultoEspañaAvatrombopag is the newest thrombopoietin receptor agonist (TPO-RA) approved to treat immune thrombocytopenia (ITP). Real-world evidence regarding effectiveness/safety is limited. The Spanish ITP Group (GEPTI) performed a retrospective study with patients starting avatrombopag for the first time. A total of 268 ITP patients were recruited. The median (interquartile range [IQR]) follow-up time was 47.5 (30.4-58.9) weeks. Among the 193 patients with baseline platelet counts <50 × 109/L, 174 (90.1%) of them achieved response (PC ≥50 × 109/L), and 113 (87.6%) of the 129 who persisted on avatrombopag at last visit had platelet levels above such threshold. Results were similar when only those patients switching to avatrombopag due to previous treatment failure were considered (n = 104). Patients reached response in 13 (7-21) days. Among patients with baseline levels ≥50 × 109/L, 73/75 (97.3%) reported response, which was maintained by 53 (94.6%) of the 56 who continued on avatrombopag at the end of the study. Loss-of-response was always <10%. ITP duration did not influence response. Approximately 79% (34/43) of heavily pretreated (≥4 lines) patients with baseline platelet counts <50 × 109/L switching after previous failure achieved PC ≥50 × 109/L. Previous use of eltrombopag and/or romiplostim did not influence response, regardless of whether previous TPO-RA(s) succeeded or failed. Avatrombopag allowed dose-reduction/suspension of corticosteroids in 40/50 (80.0%) patients with baseline platelet counts <50 × 109/L. Overall, 40/268 (14.9%) thrombocytosis and 12/268 (4.5%) thromboembolic events were reported. Our real-world cohort supports the use of avatrombopag to manage ITP, regardless of disease severity and treatment history.Wiley20242024-12-0120242024-12-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/21308reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/213082026-06-22T12:44:07Z |
| dc.title.none.fl_str_mv |
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI) |
| title |
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI) |
| spellingShingle |
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI) Pascual-Izquierdo, Cristina Receptors, Thrombopoietin Aged Spain Adult Humans Hydrazines Middle Aged Pyrazoles Thiazoles Male Thiophenes Platelet Count Female Treatment Outcome Purpura, Thrombocytopenic, Idiopathic Retrospective Studies Púrpura Trombocitopénica Idiopática Resultado del Tratamiento Tiofenos Receptores de Trombopoyetina Femenino Tiazoles Masculino Recuento de Plaquetas Humanos Persona de Mediana Edad Hidrazinas Pirazoles Anciano Estudios Retrospectivos Adulto España |
| title_short |
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI) |
| title_full |
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI) |
| title_fullStr |
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI) |
| title_full_unstemmed |
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI) |
| title_sort |
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI) |
| dc.creator.none.fl_str_mv |
Pascual-Izquierdo, Cristina Sánchez-González, Blanca Canaro Hirnyk, Mariana García-Donas, Gloria Menor-Gómez, María Gil-Fernández, Juan-José Monsalvo-Saornil, Silvia de-Laiglesia, Almudena Álvarez-Román, María Teresa Jarque-Ramos, Isidro Llácer, María-José Pedrote-Amador, Begoña Zafra-Torres, Denis Caparrós-Miranda, Isabel Socorro Ortúzar-Pasalodos, Ariana Revilla-Calvo, Nuria Bastida, José-María Chica-Gullón, Esther Alvarellos, Montserrat Jiménez-Bárcenas, Reyes Bernat-Pablo, Silvia Martínez-Carballeira, Daniel Lakhwani, Sunil López-Ansoar, Elsa Moreno-Beltrán, María-Esperanza Lorenzo-Vizcaya, Álvaro Aguirre, María-Aránzazu Lasa-Eguialde, Maialen Canet, Marta González-Gascón-Y-Marín, Isabel-Teresa Caballero-Navarro, Gonzalo Cuesta, Amalia Díaz-López, Marta Arquero, Teresa Moreno-Carbonell, Marta Mingot-Castellano, María-Eva |
| author |
Pascual-Izquierdo, Cristina |
| author_facet |
Pascual-Izquierdo, Cristina Sánchez-González, Blanca Canaro Hirnyk, Mariana García-Donas, Gloria Menor-Gómez, María Gil-Fernández, Juan-José Monsalvo-Saornil, Silvia de-Laiglesia, Almudena Álvarez-Román, María Teresa Jarque-Ramos, Isidro Llácer, María-José Pedrote-Amador, Begoña Zafra-Torres, Denis Caparrós-Miranda, Isabel Socorro Ortúzar-Pasalodos, Ariana Revilla-Calvo, Nuria Bastida, José-María Chica-Gullón, Esther Alvarellos, Montserrat Jiménez-Bárcenas, Reyes Bernat-Pablo, Silvia Martínez-Carballeira, Daniel Lakhwani, Sunil López-Ansoar, Elsa Moreno-Beltrán, María-Esperanza Lorenzo-Vizcaya, Álvaro Aguirre, María-Aránzazu Lasa-Eguialde, Maialen Canet, Marta González-Gascón-Y-Marín, Isabel-Teresa Caballero-Navarro, Gonzalo Cuesta, Amalia Díaz-López, Marta Arquero, Teresa Moreno-Carbonell, Marta Mingot-Castellano, María-Eva |
| author_role |
author |
| author2 |
Sánchez-González, Blanca Canaro Hirnyk, Mariana García-Donas, Gloria Menor-Gómez, María Gil-Fernández, Juan-José Monsalvo-Saornil, Silvia de-Laiglesia, Almudena Álvarez-Román, María Teresa Jarque-Ramos, Isidro Llácer, María-José Pedrote-Amador, Begoña Zafra-Torres, Denis Caparrós-Miranda, Isabel Socorro Ortúzar-Pasalodos, Ariana Revilla-Calvo, Nuria Bastida, José-María Chica-Gullón, Esther Alvarellos, Montserrat Jiménez-Bárcenas, Reyes Bernat-Pablo, Silvia Martínez-Carballeira, Daniel Lakhwani, Sunil López-Ansoar, Elsa Moreno-Beltrán, María-Esperanza Lorenzo-Vizcaya, Álvaro Aguirre, María-Aránzazu Lasa-Eguialde, Maialen Canet, Marta González-Gascón-Y-Marín, Isabel-Teresa Caballero-Navarro, Gonzalo Cuesta, Amalia Díaz-López, Marta Arquero, Teresa Moreno-Carbonell, Marta Mingot-Castellano, María-Eva |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
|
| dc.subject.none.fl_str_mv |
Receptors, Thrombopoietin Aged Spain Adult Humans Hydrazines Middle Aged Pyrazoles Thiazoles Male Thiophenes Platelet Count Female Treatment Outcome Purpura, Thrombocytopenic, Idiopathic Retrospective Studies Púrpura Trombocitopénica Idiopática Resultado del Tratamiento Tiofenos Receptores de Trombopoyetina Femenino Tiazoles Masculino Recuento de Plaquetas Humanos Persona de Mediana Edad Hidrazinas Pirazoles Anciano Estudios Retrospectivos Adulto España |
| topic |
Receptors, Thrombopoietin Aged Spain Adult Humans Hydrazines Middle Aged Pyrazoles Thiazoles Male Thiophenes Platelet Count Female Treatment Outcome Purpura, Thrombocytopenic, Idiopathic Retrospective Studies Púrpura Trombocitopénica Idiopática Resultado del Tratamiento Tiofenos Receptores de Trombopoyetina Femenino Tiazoles Masculino Recuento de Plaquetas Humanos Persona de Mediana Edad Hidrazinas Pirazoles Anciano Estudios Retrospectivos Adulto España |
| description |
Avatrombopag is the newest thrombopoietin receptor agonist (TPO-RA) approved to treat immune thrombocytopenia (ITP). Real-world evidence regarding effectiveness/safety is limited. The Spanish ITP Group (GEPTI) performed a retrospective study with patients starting avatrombopag for the first time. A total of 268 ITP patients were recruited. The median (interquartile range [IQR]) follow-up time was 47.5 (30.4-58.9) weeks. Among the 193 patients with baseline platelet counts <50 × 109/L, 174 (90.1%) of them achieved response (PC ≥50 × 109/L), and 113 (87.6%) of the 129 who persisted on avatrombopag at last visit had platelet levels above such threshold. Results were similar when only those patients switching to avatrombopag due to previous treatment failure were considered (n = 104). Patients reached response in 13 (7-21) days. Among patients with baseline levels ≥50 × 109/L, 73/75 (97.3%) reported response, which was maintained by 53 (94.6%) of the 56 who continued on avatrombopag at the end of the study. Loss-of-response was always <10%. ITP duration did not influence response. Approximately 79% (34/43) of heavily pretreated (≥4 lines) patients with baseline platelet counts <50 × 109/L switching after previous failure achieved PC ≥50 × 109/L. Previous use of eltrombopag and/or romiplostim did not influence response, regardless of whether previous TPO-RA(s) succeeded or failed. Avatrombopag allowed dose-reduction/suspension of corticosteroids in 40/50 (80.0%) patients with baseline platelet counts <50 × 109/L. Overall, 40/268 (14.9%) thrombocytosis and 12/268 (4.5%) thromboembolic events were reported. Our real-world cohort supports the use of avatrombopag to manage ITP, regardless of disease severity and treatment history. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024 2024-12-01 2024 2024-12-01 |
| dc.type.none.fl_str_mv |
research article http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/20.500.13003/21308 |
| url |
https://hdl.handle.net/20.500.13003/21308 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Wiley |
| publisher.none.fl_str_mv |
Wiley |
| dc.source.none.fl_str_mv |
reponame:Docusalut instname:Conselleria de Salut i Consum del Govern de les Illes Balears |
| instname_str |
Conselleria de Salut i Consum del Govern de les Illes Balears |
| reponame_str |
Docusalut |
| collection |
Docusalut |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869420769146044416 |
| score |
15.812455 |